Table 4 Multiple logistic regression comparing survival and duration of initiation of Tocilizumab.

From: Tocilizumab as a targeted immunomodulatory therapy in the management of severe respiratory illnesses: a multicenter cohort study of COVID-19 patients

Characteristics

OR

95% CI

p-value

Overall hospital survival

1.33

1.05–1.68

0.015**

ICU survival rate

1.41

1.11–1.77

0.004**

Duration from ICU admission to initiation of Tocilizumab

1.04

1.01–1.07

0.010**

  1. The odds ratios (OR) and 95% confidence intervals (CI) were calculated to estimate the strength and direction of the associations.
  2. **Significant, if p-value < 0.05.
Back to article page